UK Markets closed

MYL Dec 2021 20.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
2.1200-0.1300 (-5.78%)
As of 2:31PM EDT. Market open.
Full screen
Previous close2.2500
Open2.1200
Bid1.8900
Ask2.7200
Strike20.00
Expiry date2021-12-17
Day's range2.1200 - 2.1200
Contract rangeN/A
Volume1
Open interest976
  • Mylan (MYL) Q2 Earnings Beat Estimates, Revenues Fall Y/Y
    Zacks

    Mylan (MYL) Q2 Earnings Beat Estimates, Revenues Fall Y/Y

    Mylan (MYL) beats on both earnings and revenues for the second quarter of 2020.

  • Mylan (MYL) Surpasses Q2 Earnings and Revenue Estimates
    Zacks

    Mylan (MYL) Surpasses Q2 Earnings and Revenue Estimates

    Mylan (MYL) delivered earnings and revenue surprises of 16.84% and 1.08%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Mylan narrows annual revenue estimates on COVID-19 pressure
    Reuters

    Mylan narrows annual revenue estimates on COVID-19 pressure

    Generic drugmakers like Mylan benefited in the first quarter from customers stocking up on over-the-counter medicines ahead of the lockdowns imposed to curb the spread of the virus. The stockpiling, however, meant that patients bought fewer drugs in the second quarter, weighing on sales outside North America and the company now expects 2020 revenue of between $11.5 billion and $12.0 billion, versus up to $12.50 billion previously. Mylan, which sells a cheaper version of Gilead Sciences Inc's COVID-19 drug remdesivir, took a roughly 5% hit to sales of products in Europe and the rest of the world as non-COVID-19 related hospital visits fell during the pandemic.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more